Status:

UNKNOWN

Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma

Lead Sponsor:

Children's Cancer and Leukaemia Group

Conditions:

Liver Cancer

Eligibility:

All Genders

Up to 20 years

Phase:

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase...

Detailed Description

OBJECTIVES: Primary * Determine the biological activity of irinotecan hydrochloride, when given on a prolonged schedule, in terms of response rate and rate of early progression, in young patients wi...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of hepatoblastoma
  • Refractory or recurrent disease
  • Failed prior first-line or second-line treatment
  • Metastatic disease allowed
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
  • Elevated serum alpha-fetoprotein (AFP) allowed
  • No hepatocellular carcinoma
  • PATIENT CHARACTERISTICS:
  • Lansky performance status 50-100% in patients ≤ 10 years of age OR Karnofsky performance status 50-100% in patients \> 10 years of age
  • Life expectancy \> 8 weeks
  • Hemoglobin \> 8 g/dL
  • Absolute neutrophil count \> 1,000/mm\^3
  • Platelet count \> 100,000/mm\^3
  • Serum bilirubin ≤ 2 times normal
  • AST/ALT ≤ 2 times normal
  • Serum creatinine ≤ 3 times normal
  • Normal metabolic parameters (i.e., serum electrolytes, glucose, calcium, and phosphate)
  • Not pregnant or nursing
  • No severe uncontrolled infection or enterocolitis
  • PRIOR CONCURRENT THERAPY:
  • Recovered from toxicity of prior therapy
  • No chemotherapy within 3 weeks prior to study entry
  • No prior irinotecan
  • No other concurrent anticancer therapy

Exclusion

    Key Trial Info

    Start Date :

    April 1 2003

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT00287976

    Start Date

    April 1 2003

    Last Update

    September 17 2013

    Active Locations (22)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 6 (22 locations)

    1

    Our Lady's Hospital for Sick Children Crumlin

    Dublin, Ireland, 12

    2

    Emma Kinderziekenhuis

    Amsterdam, Netherlands, NL-1100 DE

    3

    Birmingham Children's Hospital

    Birmingham, England, United Kingdom, B4 6NH

    4

    Institute of Child Health at University of Bristol

    Bristol, England, United Kingdom, BS2 8AE